Skip to main content
logo
Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
2.680
-0.030 (-1.11%)
At close: Oct 12, 2026, 4:00 PM EDT
2.800
+0.120 (4.48%)
Pre-market: Oct 13, 2026, 7:00 AM EDT

Seres Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
1.880.79---144.93
Revenue Growth
-----336.33%
Gross Profit
-46.08-54.82-68.13-117.6-109.653.04
Operating Income
-78.23-93.97-121.32-195.1-179.91-64.49
Net Income
-22.465.70.14-113.72-250.16-65.58
Earnings Per Share
-2.410.640.00-17.77-46.29-14.30
EPS Growth
-14333.92%----

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
15.5945.7730.79127.97181.34290.71
Total Debt
56.6482.9791.64198.78162.5949.21
Net Cash (Debt)
-41.05-37.2-60.85-70.8218.75241.5
Net Cash Growth
-----92.23%13.46%
Net Cash Per Share
-4.40-4.19-7.83-11.063.4752.67

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-51.261.12-148.61-117.35-228.826.69
Capital Expenditures
-0.04-0.25-0.38-7.98-9.82-9.57
Free Cash Flow
-51.30.87-148.99-125.33-238.64-2.88
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-----2.10%
Operating Margin
-4154.38%-11910.14%----44.50%
Pretax Margin
-1192.94%721.93%----45.25%
Profit Margin
-1192.94%721.93%----45.25%
FCF Margin
-2724.11%109.63%----1.99%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingOct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
-23.631043.26---
P/FCF Ratio
-155.62----
PS Ratio
14.30170.61---5.28